Nuclear medicine perspective on radioimmunotherap

Published: June 8, 2009
Abstract Views: 362
PDF: 258
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Radioimmunotherapy is a new type of therapy that targets radiation to the tumor using monoclonal antibodies (MAbs). The use of radiolabeled MAbs as a potential cancer treatment was first explored in the ‘50s. Only in the ‘70s, however, technological advancements allowed for the design and production of monoclonal antibodies directed against specific cellular antigens. The feasibility of combining a monoclonal antibodies directed against specific tumor-associated antigens with a radioisotope in order to deliver a therapeutic dose of radiation to a tumor cell has been studied since the early ‘80s.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Fanti, S., Montini, G., & Farsad, M. (2009). Nuclear medicine perspective on radioimmunotherap. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.395